The agreement provides for R&D into acne formulations based on Skinvisible’s Invisicare technology and benzoyl peroxide (BPO) manufactured by Cambrex. In addition, the two companies will share marketing responsibilities for the products that are developed under this agreement.
Steve Klosk, president and CEO of Cambrex, said: “This collaboration with Skinvisible will enable us to provide our clients with technology-enhanced delivery options for our BPO products.
“We are excited to have the opportunity to associate our active pharmaceutical ingredients with Skinvisible’s innovative technology. We foresee that this value-added approach is an advantage for our clients and acne patients.”